

Margaret von Mehren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/554685/publications.pdf>

Version: 2024-02-01

102
papers

17,928
citations

94269

37
h-index

34900

98
g-index

104
all docs

104
docs citations

104
times ranked

10912
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 1291-1300.	0.8	24
2	ASO Visual Abstract: National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma—A Modern Appraisal of Variability in Therapeutic Strategies. <i>Annals of Surgical Oncology</i> , 2022, 29, 2288-2289.	0.7	2
3	INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib. <i>Journal of Clinical Oncology</i> , 2022, 40, 359881-359881.	0.8	14
4	Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers. <i>Clinical Cancer Research</i> , 2022, 28, 1268-1276.	3.2	7
5	Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?. <i>Current Treatment Options in Oncology</i> , 2022, 23, 749-761.	1.3	5
6	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	0.8	15
7	Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021, 127, 729-738.	2.0	30
8	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , 2021, 26, e639-e649.	1.9	29
9	Gastrointestinal stromal tumours. <i>Nature Reviews Disease Primers</i> , 2021, 7, 22.	18.1	169
10	Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. <i>BMC Cancer</i> , 2021, 21, 291.	1.1	12
11	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. <i>European Journal of Cancer</i> , 2021, 145, 132-142.	1.3	75
12	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96
13	Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 3565-3574.	1.3	6
14	<sc><i>SMARCA2</i></sc> is a novel fusion gene of extraskeletal myxoid chondrosarcoma identified by <sc>RNA</sc> next-generation sequencing. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 709-712.	1.5	13
15	Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor. <i>Cancers</i> , 2021, 13, 3699.	1.7	2
16	Early and Next-Generation KIT/PDGFR Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 672500.	1.3	35
17	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2021, 155, 236-244.	1.3	19
18	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFR</i> Mutations in the Phase III INVICTUS Study. <i>Clinical Cancer Research</i> , 2021, 27, 6333-6342.	3.2	25

#	ARTICLE	IF	CITATIONS
19	Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis. <i>Cancers</i> , 2021, 13, 4816.	1.7	25
20	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	0.8	56
21	Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment. <i>JCI Insight</i> , 2021, 6, .	2.3	5
22	National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma: A Modern Appraisal of Variability in Therapeutic Strategies. <i>Annals of Surgical Oncology</i> , 2021, , 1.	0.7	2
23	Deciding on the duration of adjuvant therapy in gastrointestinal stromal tumor. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 547-556.	1.1	0
24	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. <i>Future Oncology</i> , 2020, 16, 4251-4264.	1.1	43
25	Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 1837-1845.	3.2	32
26	Treatment Patterns and Distance to Treatment Facility for Soft Tissue Sarcoma of the Extremity. <i>Journal of Surgical Research</i> , 2020, 256, 492-501.	0.8	4
27	Ripretinib for advanced gastrointestinal stromal tumours – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e415.	5.1	4
28	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020, 38, 3294-3303.	0.8	61
29	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 923-934.	5.1	224
30	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2020, 21, 935-946.	5.1	186
31	Quality of life (QoL) and self-reported function with ripretinib in 4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11535-11535.	0.8	8
32	Retroperitoneal Sarcomas: Does Laterality Matter?. <i>Journal of Surgical Research</i> , 2019, 244, 34-41.	0.8	5
33	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. <i>Cancer</i> , 2019, 125, 4435-4441.	2.0	10
34	Soft tissue sarcoma of the extremity: Characterizing symptom duration and outcomes. <i>Surgical Oncology</i> , 2019, 29, 190-195.	0.8	4
35	Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage. <i>Sarcoma</i> , 2019, 2019, 1-8.	0.7	4
36	Clinical activity of avapritinib in 4th-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11022-11022.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Granular cell tumor experience at a comprehensive cancer center. <i>Journal of Surgical Research</i> , 2018, 226, 1-7.	0.8	23
38	Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. <i>JAMA Oncology</i> , 2018, 4, 814.	3.4	26
39	Gastrointestinal Stromal Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 136-143.	0.8	206
40	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. <i>International Journal of Molecular Sciences</i> , 2018, 19, 732.	1.8	29
41	A retrospective natural history study of patients (pts) with PDGFR [±] D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11533-11533.	0.8	2
42	Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2017, 23, 171-180.	3.2	31
43	Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, 523-528.	0.8	58
44	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results. <i>JAMA Oncology</i> , 2017, 3, 944.	3.4	73
45	Randomized Clinical Trials in Gastrointestinal Stromal Tumors. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 545-557.	0.6	1
46	Emerging drugs for the treatment of gastrointestinal stromal tumour. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 317-329.	1.0	6
47	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. <i>Gynecologic Oncology</i> , 2017, 146, 531-537.	0.6	51
48	SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. <i>Cancer</i> , 2016, 122, 868-874.	2.0	80
49	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2016, 61, 94-101.	1.3	25
50	Management of Gastrointestinal Stromal Tumors. <i>Surgical Clinics of North America</i> , 2016, 96, 1059-1075.	0.5	13
51	Efficacy of trabectedin for the treatment of liposarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1953-1962.	0.9	12
52	Molecular Subtypes of KIT/PDGFR Wild-Type Gastrointestinal Stromal Tumors. <i>JAMA Oncology</i> , 2016, 2, 922.	3.4	291
53	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 786-793.	0.8	647
54	Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11010-11010.	0.8	15

#	ARTICLE	IF	CITATIONS
55	Patterns of Chemotherapy Administration in High-Risk Soft Tissue Sarcoma and Impact on Overall Survival. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1366-1374.	2.3	37
56	Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case. BMC Cancer, 2015, 15, 887.	1.1	30
57	Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology, 2015, 75, 1047-1055.	1.1	5
58	Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging. Cancer Biology and Therapy, 2014, 15, 911-918.	1.5	3
59	Differential Expression of Cysteine Dioxygenase 1 in Complex Karyotype Liposarcomas. Biomarkers in Cancer, 2014, 6, BIC.S14683.	3.6	4
60	A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Investigational New Drugs, 2014, 32, 518-525.	1.2	16
61	GIST Treatment Options after Tyrosine Kinase Inhibitors. Current Treatment Options in Oncology, 2014, 15, 493-506.	1.3	25
62	Challenges in the treatment of angiosarcoma: a single institution experience. American Journal of Surgery, 2014, 208, 254-259.	0.9	32
63	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology, 2014, 32, 1563-1570.	0.8	252
64	Gastrointestinal Stromal Tumors, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 853-862.	2.3	96
65	Soft Tissue Sarcoma, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 473-483.	2.3	84
66	Peripheral primitive neuroectodermal tumor of the dura in a 51-year-old woman following intensive treatment for breast cancer. American Journal of Case Reports, 2014, 15, 294-299.	0.3	17
67	Gastrointestinal Stromal Tumors. Hematology/Oncology Clinics of North America, 2013, 27, 905-920.	0.9	31
68	Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes and Cancer, 2013, 52, 214-224.	1.5	63
69	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 295-302.	6.3	1,144
70	Head and Neck Sarcomas: A Comprehensive Cancer Center Experience. Cancers, 2013, 5, 890-900.	1.7	47
71	Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2012, 30, 2401-2407.	0.8	232
72	Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132. Annals of Surgical Oncology, 2012, 19, 1074-1080.	0.7	175

#	ARTICLE	IF	CITATIONS
73	Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. <i>Cancer</i> , 2012, 118, 770-776.	2.0	98
74	Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing?. <i>Cancer Treatment Reviews</i> , 2011, 37, 291-299.	3.4	61
75	NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-1-S-41.	2.3	1,004
76	Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 3141-3147.	0.8	352
77	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009, 373, 1097-1104.	6.3	1,233
78	Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?. <i>Oncology</i> , 2009, 23, 65-6.	0.4	6
79	Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>c-KIT</i> . <i>Journal of Clinical Oncology</i> , 2008, 26, 620-625.	0.8	922
80	Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 5360-5367.	0.8	560
81	Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8387-8392.	3.3	225
82	Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. <i>Journal of Clinical Oncology</i> , 2008, 26, 626-632.	0.8	951
83	The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors. <i>Current Opinion in Oncology</i> , 2008, 20, 428-432.	1.1	15
84	Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1145-1154.	1.1	15
85	New therapeutics for soft-tissue sarcomas in adults. <i>Oncology</i> , 2007, 21, 123-6.	0.4	2
86	Beyond Imatinib: Second Generation c-KIT Inhibitors for the Management of Gastrointestinal Stromal Tumors. <i>Clinical Colorectal Cancer</i> , 2006, 6, S30-S34.	1.0	33
87	Gastrointestinal Stromal Tumors. , 2006, , 418-429.		0
88	Imatinib-refractory gastrointestinal stromal tumors: The clinical problem and therapeutic strategies. <i>Current Oncology Reports</i> , 2006, 8, 192-197.	1.8	16
89	Therapeutic Effect of Imatinib in Gastrointestinal Stromal Tumors: AKT Signaling Dependent and Independent Mechanisms. <i>Cancer Research</i> , 2006, 66, 5477-5486.	0.4	72
90	Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 4764-4774.	0.8	746

#	ARTICLE	IF	CITATIONS
91	Role of New Chemotherapy Agents in Soft Tissue Sarcoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 198-205.	2.3	0
92	Colorectal cancer vaccines: What we know and what we don't yet know. Seminars in Oncology, 2005, 32, 76-84.	0.8	5
93	Gastrointestinal Stromal Tumors. Hematology/Oncology Clinics of North America, 2005, 19, 547-564.	0.9	32
94	New Therapeutic strategies for soft tissue sarcomas. Current Treatment Options in Oncology, 2003, 4, 441-451.	1.3	13
95	Recent advances in the management of gastrointestinal stromal tumors. Current Oncology Reports, 2003, 5, 288-294.	1.8	14
96	Monoclonal Antibody Therapy for Cancer. Annual Review of Medicine, 2003, 54, 343-369.	5.0	175
97	Gastrointestinal Stromal Tumors: A Paradigm for Molecularly Targeted Therapy. Cancer Investigation, 2003, 21, 553-563.	0.6	15
98	Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2003, 21, 4342-4349.	0.8	2,160
99	Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. New England Journal of Medicine, 2002, 347, 472-480.	13.9	4,018
100	Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunology, Immunotherapy, 1997, 44, 265-272.	2.0	19
101	Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins. Cancer Immunology, Immunotherapy, 1997, 45, 190-192.	2.0	15
102	Pharmacotherapy of gastrointestinal stromal tumours. , 0, .		1